AVA 001

Drug Profile

AVA 001

Alternative Names: AVA-101; AVA-201; rAAV.sFlt-1

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avalanche Biotechnologies
  • Developer Adverum Biotechnologies
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion
  • Research Wet age-related macular degeneration

Most Recent Events

  • 01 Aug 2017 Avalanche Biotechnologies completes a phase I/II trial for Wet age-related macular degeneration (In the elderly) in Australia (Intraocular) (NCT01494805)
  • 02 Sep 2015 Preclinical trials in Diabetic macular oedema and Retinal vein occlusion in USA (Intraocular) before September 2015 (Avalanche Biotechnologies Pipeline, September 2015)
  • 24 Aug 2015 Avalanche Biotechnologies has patents pending for AVA 101/AVA 201 in several countries worldwide (Avalanche 10-K, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top